ABVC BioPharma (NASDAQ:ABVC) Releases Earnings Results, Beats Estimates By $0.36 EPS

ABVC BioPharma (NASDAQ:ABVC) released its quarterly earnings data on Tuesday. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.36, FiscalAI reports.

ABVC BioPharma Price Performance

Shares of ABVC stock traded down $0.05 during trading on Thursday, reaching $0.94. The company had a trading volume of 10,485 shares, compared to its average volume of 99,662. The firm’s 50 day simple moving average is $1.02 and its two-hundred day simple moving average is $1.22. ABVC BioPharma has a one year low of $0.71 and a one year high of $3.06. The company has a market capitalization of $25.22 million, a PE ratio of -3.26 and a beta of 0.47.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners. ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.